Preclinical toxicity studies of kahalalide F, a new anticancer agent: Single and multiple dosing regimens in the rat

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 4, 2002, Pages 333-340

  Brown, Alan P ^a   Morrissey, Robert L ^b   Faircloth, Glynn T ^c   Levine, Barry S ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Pathology Associates   (United States)

^c PharmaMar USA Inc   (United States)

Author keywords

Antitumor; Cancer chemotherapeutic; Cytotoxic; Kidney toxicity; Nervous system; Renal toxicity

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BILE ACID; CHLORIDE; CHOLESTEROL; CREATININE; GLOBULIN; KAHALALIDE F; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL HYPERPLASIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DOSE CALCULATION; DOSE RESPONSE; DRUG CYTOTOXICITY; FEMALE; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY MASS; LETHALITY; MALE; MAXIMUM TOLERATED DOSE; MICROSCOPY; NEPHROTOXICITY; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; UREA NITROGEN BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; FEMALE; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY DISEASES; MALE; MAXIMUM TOLERATED DOSE; ORGAN SIZE; PEPTIDES; RATS;

EID: 0036392375     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0499-2     Document Type: Article

References (13)

1. Brin MF (1997) Botulinum toxin: chemistry, pharmacology, toxicity and immunology. Muscle Nerve [Suppl 6]:S146
2. Faircloth G, Grant W, Smith B, Supko J, Brown A, Geldof A, Jimeno J (2000) Preclinical development of kahalalide F, a new marine compound selected for clinical studies. Proc Am Assoc Cancer Res 41:600
3. Faircloth GT, Smith B, Grant W, Jimeno J, Garcia-Gravalos L, Scotto K, Shtil A (2001) Selective antitumor activity of kahalalide F, a marine-derived cyclic depsipeptide. Proc Am Assoc Cancer Res 42:213
4. Garcia-Rocha M, Bonay P, Avila J (1996) The antitumoral compound kahalalide F acts on cell lysosomes. Cancer Lett 99:43
5. Lopez-Macia A, Jimenez JC, Royo M, Giralt E, Albericio F (2001) Synthesis and structure determination of kahalalide F. J Am Chem Soc 123:11398
6. Luber-Narod J, Smith B, Grant W, Jimeno JM, Lopez-Lazaro L, Scotto K, Shtil A, Faircloth GT (2000) In vitro safety toxicology of kahalalide F, a marine natural product with chemotherapeutic potential against selected solid tumors. Clin Cancer Res [Suppl] 6:4510s
7. Medina LA, Gomez L, Cerna C, Faircloth G, Yochmowitz M, Weitman S (2001) Investigation of the effects of kahalalide F (PM92102) against human tumor specimens taken directly from patients. Proc Am Assoc Cancer Res 42:213
8. Montecucco C, Schiavo G (1995) Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 28:423
9. Parker SL, Tong T, Bolden S, Winger PA (1997) Cancer statistics 1997. CA Cancer J Clin 47:5
10. Ripple GH, Wilding G (1999) Drug development in prostate cancer. Semin Oncol 26:217
11. Ruijter E, Van de Kaaa C, Miller G, Ruiter D, Debruyne F, Schalken J (1999) Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 20:22
12. Schellens JH, Rademaker JL, Horenblas S, Meinhardt W, Stokvis E, De Reijke TM, Jimeno JM, Lopez Lazaro L, Lopez Martin JA, Beijnen JH (2001) Phase I and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 29 October to 2 November 2001. Clin Cancer Res [Suppl] 7
13. Shao L, Weissbach L, Faircloth GT, Chabner BA, Hornicek FJ (2001) In vitro anti-proliferative eBect on sarcoma cells by ET-743 and other marine chemotherapeutics. Proc Am Assoc Cancer Res 42:203